Pages
- About
- Board of Directors
- Careers
- Clinical Experience
- Clinical Monitoring Management
- Clinical Services
- ClinicReady
- Contact Us
- Data & Biostats
- Data Management Services
- Disclaimer
- eClinical Solutions
- Experience
- FAQ
- Home
- Medical Writing
- News & Events
- Our Team
- Privacy Policy
- Project Management
- Quality Assurance
- Safety and Pharmacovigilance
- Sitemap
- Statistical and Pharmacokinetics Services
- Terms & Conditions
- The Australian Advantage
News
- Avance Clinical Featured in Endpoints News
- COVID-19 and the APAC CRO Landscape | Avance Clinical featured in Biospectrum Asia
- News: Avance Clinical Adds Oracle Argus Safety and Pharmacovigilance Platform to its Clinical Technology Solutions
- AUSTRALIA & ASIA-PACIFIC CRO MARKET REPORT: Frost & Sullivan
- ENDPOINTS NEWS: How Innovative Technologies and a Dedicated Site Network is Driving Patient Recruitment for Biotech Clinical Trials in Australia
- Client News: Avance Clinical Client Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
- Avance Clinical Wins MasterControl 2020 Innovation Excellence Award
- Biotechs get scalable early to late phase clinical offering from Cromos Pharma and Avance Clinical collaboration in Australia and Europe
- News: Avance Clinical Client Atossa Therapeutics Announces Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
- News: Avance Clinical 'ClinicReady' Featured in Endpoints News
- Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America
- News: Jorgen Mould PhD, BSc (Hons) joins Avance Clinical as Scientific Affairs Specialist
- News: Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
- Avance Clinical Client Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19
- News | Mike Watson Appointed Avance Clinical Director, Business Development, USA
- News | Avance Clinical Joins Medrio’s ‘Trial Talks’ Podcast about Why Clinical Trials are Thriving in Australia
- News | Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa’s Second COVID-19 Therapeutic Development Program
- News | Avance Clinical Wins Frost & Sullivan “2020 Asia-Pacific CRO Market Leadership Award”
- Avance Clinical Webinar & Podcast Series | Register here
- Press Release: TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020
- Premier of South Australia Steven Marshall Briefed on $50 billion Clinical Trial Sector During Visit to Adelaide-based Avance Clinical
- Endpoints News: About Avance Clinical's Oncology Capabilities
- Webinar | Why biotechs are heading to Australia with Avance Clinical for their oncology trials
- News Article | Avance reports 34% rise in clinical trials in Australia and New Zealand
- Press Release | Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis
- Avance Clinical on the Top Reasons APAC Biotech Clients Chose Australia for Clinical Trials
- Video | About Avance Clinical COVID-19 capabilities
- Avance Clinical Joins Industry Leaders at Conference Discussing The Future of Medicinal Cannabis
- Soniclean Celebrates International Health - Business SA 2019 Export Awards